Gain Therapeutics, Inc.
Develops allosteric small molecule therapies using an AI drug discovery platform.
GANX | US
Overview
Corporate Details
- ISIN(s):
- US36269B1052
- LEI:
- Country:
- United States of America
- Address:
- 4800 HAMPDEN LANE, 20814 BETHESDA
- Sector:
- Manufacturing
Description
Gain Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops next-generation allosteric small molecule therapies. The company utilizes its proprietary Magellan™ drug discovery platform, which combines artificial intelligence with physics-based computational models to identify novel allosteric binding sites on disease-implicated proteins. This approach aims to modulate protein function to treat diseases that are currently undruggable. The company's lead candidate, GT-02287, is in Phase I clinical trials for the treatment of GBA-Parkinson’s disease. Gain's therapeutic pipeline targets neurodegenerative diseases, lysosomal storage disorders, and other conditions with high unmet medical needs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Gain Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Gain Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Gain Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
